drugset / Trial / NCT03988530

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530

Phase 3 Completed 98 enrolled Repurposed Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up

Timeline

Start
2019-06-07
Primary completion
2020-11-23
Completion
2020-11-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Scopolamine Unknown 0.2 mg Intranasal

Indications